Meeting Posters

Utility of patient experience data (PED) & patient preference data in patient focused drug development (PFDD) (Abstract)

Frangiosa
22nd Annual Scientific Meeting

Systematic review of patient focused drug development meeting reports for conditions affecting neurodevelopment (Abstract)

Farmer
22nd Annual Scientific Meeting

Speech pause and speech rate for evaluating Alzheimer’s and mild cognitive impairment: A meta-analysis (Abstract)

Cohen
22nd Annual Scientific Meeting

Passive keypress and speech biomarkers for monitoring cognitive and psychosocial fluctuations in dementia caregivers (Abstract)

Moore
22nd Annual Scientific Meeting

Investigating conversational speech latency as a digital biomarker of schizophrenia: A comparison of manual and automated approaches (Abstract)

Zhang
22nd Annual Scientific Meeting

Task matters: A methodological comparison of speech elicitation types for machine learning classification of psychiatric disorders and controls (Abstract)

Menne
22nd Annual Scientific Meeting

A novel speech assessment protocol for measuring emotional expression: Preliminary findings (Abstract)

Menne
22nd Annual Scientific Meeting

Adjusting for sex improves the screening performance of a digital cognitive assessment in an AD memory clinic cohort (Abstract)

Tröger
22nd Annual Scientific Meeting

A psychometric evaluation of digital speech-based markers of negative symptom severity in schizophrenia spectrum disorders (Abstract)

Spilka
22nd Annual Scientific Meeting

Home-based EEG detection of REM sleep without atonia as a methodological biomarker of neurodegenerative risk (Abstract)

Sheehan
22nd Annual Scientific Meeting

Standardizing audio and video capture to assess biomarkers in clinical trials – Avoiding garbage in/garbage out (Abstract)

Newton
22nd Annual Scientific Meeting

Precision imaging drug trials: Quantifying the impact of study design on fMRI biomarker sensitivity and statistical power (Abstract)

Siegel
22nd Annual Scientific Meeting

Convergence of active and passive digital phenoptyping of changes in physical activity in younger and older adults with schizophrenia in a 52-week, open-label clinical trial of xanomeline and trospium chloride (Abstract)

Harvey
22nd Annual Scientific Meeting

Dynamic evidence integration patterns distinguish schizophrenia from healthy and psychiatric controls (Abstract)

Blanchard
22nd Annual Scientific Meeting

Choosing the appropriate rating scale for patient inclusion and primary endpoint definition in MDD trials: MADRS or HAMD? (Abstract)

zu Eulenburg
22nd Annual Scientific Meeting

Confirmatory factor analysis (CFA) for cognitive endpoint development: performance characteristics under misspecification, and implications for modeling and analysis (Abstract)

Simmatis
22nd Annual Scientific Meeting

Comparing baseline MADRS distributions by inclusionary scale use in major depression studies (Abstract)

Kott
22nd Annual Scientific Meeting

Statistical enrichment potential using the SIGH-D in an open-label lead-in trial (Abstract)

Namaky
22nd Annual Scientific Meeting

Repeated and brief assessment of real-world cognitive performance and influencing factors (Abstract)

Hernandez
22nd Annual Scientific Meeting

Exploring the relationship between NPI-C psychosis domains and CGI-S in Alzheimer’s disease psychosis (Abstract)

Machizawa
22nd Annual Scientific Meeting